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Abstract
Cell proliferation in primary and metastatic tumors is a fundamental characteristic of advanced breast cancer. Further
understanding of the mechanism underlying enhanced cell growth will be important in identifying novel prognostic
markers and therapeutic targets. Here we demonstrated that tyrosine phosphorylation of the proliferating cell nuclear
antigen (PCNA) is a critical event in growth regulation of breast cancer cells. We found that phosphorylation of PCNA at
tyrosine 211 (Y211) enhanced its association with the non-receptor tyrosine kinase c-Abl. We further demonstrated that c-
Abl facilitates chromatin association of PCNA and is required for nuclear foci formation of PCNA in cells stressed by DNA
damage as well as in unperturbed cells. Targeting Y211 phosphorylation of PCNA with a cell-permeable peptide inhibited
the phosphorylation and reduced the PCNA-Abl interaction. These results show that PCNA signal transduction has an
important impact on the growth regulation of breast cancer cells.
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Introduction
The c-Abl proto-oncogene is a multi-functional non-receptor
tyrosine kinase that shuttles between the cytoplasm and the
nucleus [1]. A substantial body of knowledge has been established
regarding the mechanisms of c-Abl in regulating cell migration,
the response to oxidative stresses, and apoptosis [2]. The c-Abl
kinase was originally identified as a frequent target of oncogenic
chromosomal translocation in hematopoietic neoplasia, but has
been increasingly recognized for its involvement in solid tumors.
In lung and breast cancers, deregulated c-Abl kinase contributes to
tumor development [2–5]. In breast cancer, activated c-Abl kinase
promotes cancer progression [4,6], while inhibition of c-Abl blocks
the transforming phenotypes by suppressing anchorage-indepen-
dent growth, inducing apoptosis, and inhibiting cell proliferation
[5]. Consistent with this, our recent study showed that increased c-
Abl expression is a frequent event in breast cancer (,40%) [7].
Proliferating cell nuclear antigen (PCNA) is the molecular
coordinator in the core DNA synthesis machinery [8–16]. PCNA
forms a homotrimeric ring encircling the DNA double helix and
acts as a molecular platform to recruit proteins involved in DNA
synthesis, cell-cycle control, and DNA-damage response and
repair [8,13,16–18]. PCNA exists in two distinct forms: the
replication-competent chromatin-bound form and the chromatin-
unbound form, which is not involved in DNA synthesis [19]. Not
much is known about how the two populations of PCNA are
regulated. We previously reported that the chromatin-bound
PCNA, but not the unbound form, was phosphorylated at Y211
(phospho-Y211) by the EGF receptor [20]. This phosphorylation
event was upregulated during the S phase of the cell cycle. Further
study demonstrated that this phosphorylation enhanced the
stability of chromatin-associated PCNA and enhanced its activity
in DNA replication.
In the current study, we identify c-Abl as a binding partner of
PCNA and show that Y211 phosphorylation of PCNA serves as a
binding signal for PCNA to associate with c-Abl under normal
growth conditions and in cells responding to DNA-damage
stresses. We further demonstrate that c-Abl promotes chromatin
association of PCNA and that Y211 phosphorylation is an
important cell growth-related event downstream of c-Abl.
Results
We tested whether Y211 phosphorylation of PCNA can serve as
a signaling event that, in turn, regulates its function. To do this, we
screened a microarray of functional domains derived from
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associated with these motifs. Synthetic peptides, encompassing the
wild-type sequence surrounding the Y211 residue or the same
peptide with phosphorylated Y211, were conjugated to a
fluorescent dye (Cy3) and used for probing the microarray (data
not shown). The Cy3-conjugated peptide with the non-phosphor-
ylated wild-type sequence did not bind to any of the functional
domains. In contrast, incubation with the phosphorylated peptide
identified the SH2 domain of the non-receptor tyrosine kinase c-
Abl as a phospho-Y211-binding motif. Further verification with
co-immunoprecipitation (co-IP) using extracts of MDA-MB-231
and BT474 cells demonstrated that PCNA and c-Abl formed a
complex in vivo (Fig. 1).
These results indicate that PCNA interacts with c-Abl, and
suggest that the interaction is mediated by Y211 phosphorylation.
To further test the importance of Y211 phosphorylation in the
Abl-PCNA interaction, wild-type PCNA or mutant PCNA in
which the Y211 residue was replaced with a phenylalanine
(Y211F) was transfected into HEK293T cells. Expression of the
transfected PCNA was at corresponding levels relative to the
endogenous PCNA (Figure S1). Endogenous c-Abl was immu-
noprecipitated with a c-Abl–specific antibody and the level of co-
precipitated ectopic PCNA was determined by western analysis.
As shown in Figure 2A, binding between the Y211F mutant and
c-Abl was reduced compared with that of wild-type PCNA,
suggesting that phosphorylation of Y211 is important for the
association between PCNA and c-Abl. To further define the role
of Y211 phosphorylation of PCNA in association with c-Abl, a
synthetic peptide containing the sequence of the proximal region
of Y211 in which the Y211 residue was replaced with
phenylalanine was used to block phosphorylation at Y211
(hereafter referred to as the Y211F peptide) [20]. As a negative
control, we used a peptide with the same amino acid residues as
the Y211F peptide but in a scrambled order (referred to hereafter
as the scramble peptide). These peptides were conjugated with the
HIV-derived TAT sequence at the N terminus, which was capable
of transducing the peptides to the nuclear compartment [21]. This
was demonstrated by the clear nuclear localization of 5(6)-
carboxyfluorescein (FAM)-labeled Y211F peptide (comparing
FAM-TAT-Y211F and FAM-Y211F in Fig. 2B). Importantly,
treatment with the Y211F peptide, but not with the same dose of
the control scramble peptide, resulted in inhibition of Y211
phosphorylation of PCNA in BT474 and MDA-MB-231 cells
(Fig. 2C), and blocked the interaction between endogenous
PCNA and c-Abl proteins in both cell lines (Fig. 2D). The
importance of Y211 phosphorylation for c-Abl interaction was
further supported by incubating cells with synthetic peptides of the
wild-type sequence with and without phosphorylation at the Y211
residue (Fig. 2E). The results showed that the phosphorylated
Y211 peptide was more potent in blocking the Abl-PCNA
interaction than the non-phosphorylated counterpart. Taken
together, these results indicate that phosphorylation of Y211 on
PCNA is critical for the interaction between PCNA and c-Abl.
To test the impact of inhibiting Y211 phosphorylation of PCNA
in breast cancer cell growth, MDA-MB-231 (Fig. 3A) and BT474
(Fig. 3B) cells were treated with the Y211F peptide or the control
peptide. Treatment with the Y211F peptide inhibited growth in
both cell lines in a dose-dependent manner, indicating that Y211
phosphorylation is a critical event in breast cancer cells. Indeed,
targeting Y211 phosphorylation by the Y211F peptide suppressed
proliferation of MDA-MB-231 (Fig. 4) and BT474 (Fig. 5) cells.
Flow cytometry analysis showed that MDA-MB-231 cells treated
with the Y211F peptide revealed a significantly increased
proportion of cells in the S phase and decreased the proportion in
the G2-M phase of the cell cycle, while cells treated with the control
scramble peptide had cell cycle distributions similar to the mock-
treated cells (Fig. 4A). The cells accumulated in the S phase were
not engaged in DNA synthesis. This was revealed by BrdU
incorporation analysis showing that treatment with the Y211F
peptide resulted in reduced DNA synthesis activity per viable cell
(Fig. 4B). Similar effects were observed in BT474 cells (Fig. 5).
These results suggest that Y211 phosphorylation of PCNA conveys
a growth-promoting function partly through its interaction with c-
Abl. To further determine whether Y211 phosphorylation cooper-
ates with c-Abl in enhancing cell growth, BT474 cells harboring
shRNA against c-Abl (shAbl) or control shRNA of scrambled
sequence (shCtrl) were treated with the Y211F or the scramble
peptide (Fig. 5C). While Y211F peptide treatment significantly
inhibited the growth of BT474/shLuc cells, the growth inhibition
waspartiallyrescuedbyknockingdownc-AblexpressioninBT474/
shAbl cells. The reduced sensitivity of BT474/shABL cells to the
Y211F peptide is consistent with the notion that c-Abl enhances cell
growth at least in part through Y211 phosphorylation.
To further define the mechanism by which c-Abl–PCNA
interaction is regulated and to discern the functional consequences
of this interaction, cells were treated with or without ionizing
irradiation. We found that the levels of Y211 phosphorylation
were increased by the treatment (Fig. 6A). Lysates of these cells
were subjected to immunoprecipitation with an anti-c-Abl
antibody. The levels of co-precipitated PCNA were then
determined by western analysis (Fig. 6B). Corroborating the
observation that c-Abl interacts with PCNA through Y211
phosphorylation (Fig. 2), and that Y211 phosphorylation was
enhanced by IR treatment (Fig. 5A), the interaction between c-
Abl and PCNA was also enhanced by IR treatment. These results
taken together suggest that Y211 phosphorylation is an important
signaling event in response to DNA-damage stresses in breast
cancer cells. Indeed, blocking BT474 cells with the Y211F peptide,
but not the control scramble peptide, sensitized cells to IR
treatment (Fig. 6C). Corroborating these results, further exper-
iments demonstrated that c-Abl plays a pivotal role in promoting
the chromatin association of PCNA (Fig. 7). MDA-MB-231/
shAbl and MDA-MB-231/shCtrl cells were extracted with Triton
X-100 to isolate the chromatin-bound and chromatin-unbound
fractions of PCNA. Down-regulation of c-Abl resulted in a
significant decrease in chromatin-bound PCNA (Fig. 7A). IR
treatment led to a further reduction of the chromatin-bound form
of PCNA in both cell lines, with the MDA-MB-231/shAbl cells
containing the lowest level of chromatin-associated PCNA.
Interestingly, after IR treatment, the remaining chromatin-bound
PCNA responded to DNA-damage stress by forming sub-nuclear
foci (Fig. 7B). In the absence of stress, MDA-MB-231/shAbl cells
had moderately fewer PCNA foci-positive cells than the MDA-
Figure 1. PCNA interacts with c-Abl in vitro and in vivo.
Endogenous interaction of PCNA with c-Abl. Interaction of endogenous
PCNA and c-Abl in breast cancer cell lines BT474 cells (left panel) and
MDA-MB-231 cells (right panel) demonstrated by immunoprecipitation
with an anti–c-Abl antibody. After gel separation, the co-precipitated
PCNA and c-Abl were detected by using the corresponding antibodies.
doi:10.1371/journal.pone.0029416.g001
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induced nuclear PCNA foci in MDA-MB-231/shCtrl cells. Such
induction was not observed in MDA-MD-231/shAbl cells
(Fig. 7C). Thus, depletion of c-Abl mitigates the PCNA-mediated
DNA-damage response.
Discussion
Y211 phosphorylation of PCNA represents a mechanism by
which growthsignalingregulatesnuclearproliferation events[8,20].
The post-translational modification was known to enhance PCNA
stability on the chromatin. However, it was not known whether the
phosphorylation event could also mediate PCNA regulatory
signaling. In the current study, we demonstrated that phospho-
Y211 PCNA forms a docking site for the non-receptor tyrosine
kinase c-Abl and the resulting association with c-Abl enhances the
level of chromatin-bound PCNA, in unperturbed as well as DNA
damage-stressed cells. These results unveil the crosstalk between the
DNA replication machinery and other nuclear signaling molecules
to regulate cell growth. Given the versatile functions of PCNA in
maintaining the integrity of the genome, further exploration of the
underlying mechanisms of these functions can lead to a better
understanding of how cell signaling in the nucleus shapes the
dynamics of genomic stability in cancer cells.
Recently, He et al. reported that c-Abl interacted with PCNA
through a putative PCNA-binding motif in the SH2 domain of c-
Abl [22]. This proposed motif,with the amino acid sequence QRSI,
is located at amino acid residues 160 to 163 of the c-Abl protein
(NCBI reference sequence NP_005148.2). It was suggested by the
authors that the QXXI signature is a PCNA-interacting motif.
However, we tested mutant c-Abl in which that motif was mutated
to ARSA, as used in that report, and found that the mutant
appeared to have binding ability similar to that of the wild-type c-
Abl (Figure S2), indicating that the PCNA did not bind to c-Abl
through the QXXI motif in our experimental condition. This
discrepancy could be due to different experimental conditions and/
or the setting of the experiments. In the current study, the binding
between the transfected c-Abl and the endogenous PCNA was
assessed, while in the study by He et al. both proteins were
ectopically expressed. It is noteworthy that although different
Figure 2. Y211 phosphorylation of PCNA is important for c-Abl association. A. HEK293T cells were transfected with FLAG-tagged wild-type
or Y211F PCNA. Endogenous c-Abl was then immunoprecipitated with an anti-c-Abl antibody. The levels of co-immunoprecipitated FLAG-PCNA were
determined by western analysis. B. Left panel, representative images of MDA-MB-231 cells treated for 30 min with 7.5 mM of the indicated FAM-
labeled synthetic peptide with (FAM-TAT-Y211F) or without (FAM-Y211F) the TAT sequence conjugation. Localization of the peptides was determined
by fluorescence confocal microscopy. Scale bar=5 mm. Right panel, the numbers of cells with positive nucleus were counted in three independent
fields for each treatment and the data are plotted. ***, P,0.005. C. The Y211F peptide inhibited Y211 phosphorylation of PCNA in breast cancer cells.
The breast cancer cell lines BT474 and MDA-MB-231 were treated with 15 mM of the Y211F peptide or the control scramble peptide for 12 h. Cells
were then lysed and phospho-Y211 PCNA was immunoprecipitated by using the anti-phospho–Y211 antibody, which was then detected by western
blotting with an anti-PCNA antibody. The levels of input PCNA in the lysates are shown in the lower panel. D. The Y211F peptide inhibited the
interaction between PCNA and c-Abl. Cells were treated with the peptides as described in C, and the cell lysates were then immunoprecipitated with
an anti–c-Abl antibody. The co-precipitated PCNA and c-Abl were then examined by western analysis. E. Left panel, phospho-Y211 peptide inhibits
the interaction between PCNA and c-Abl. BT474 cells were treated with the TAT-conjugated Y211 peptide with (Y211-p) or without (WT)
phosphorylation at the Y211 residue. Cell lysates were immunoprecipitated with an anti-c-Abl antibody. The immune-complexes were analyzed with
western blotting for the levels of interacting PCNA. Right panel, the data of three independent repeats were quantitated and plotted. *, P,0.05.
doi:10.1371/journal.pone.0029416.g002
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necessarily mutually exclusive. For example, while the identified
PCNA-binding motif of c-Abl may play a role in anti-apoptosis,
interaction between Abl/SH2 with PCNA/phospho-Y211 can
confer a signaling for growth advantage in cell proliferation. Further
experiments using the corresponding c-Abl and PCNA mutants
under unperturbed and stressed conditions should be able to test
and characterize these two interaction modes.
Our previous study showed that expression of Y211-phosphor-
ylated PCNA was associated with poor overall survival in breast
cancer [20]. We recently reported that c-Abl expression is a
frequent event in breast cancer [7]. The current study provides
insight into the crosstalk between these two breast cancer markers.
We reasoned that if phospho-Y211 PCNA has a major
contribution to the growth-promoting function of c-Abl, down-
regulation of Y211 phosphorylation should have a more significant
impact on cells expressing c-Abl than cells lacking the c-Abl
function. Indeed, Y211F peptide treatment conferred a more
significant growth inhibition effect in cells expressing c-Abl than in
the cells in which c-Abl was depleted (Fig. 5C). Such functional
interaction between c-Abl and PCNA is also supported by the
observation in Figure 7 in which c-Abl depletion resulted in
mitigated foci formation of PCNA in response to DNA damage.
These results warrant further study to determine the role of Y211
phosphorylation of PCNA in response to growth stimulation and
DNA-damaging stresses. Given that enhanced proliferation
provides an essential growth advantage to cancer cells in primary
tumors and in metastatic lesions and that cancer cells likely
constitute the major proliferative compartment in a cancer patient,
exploiting the proliferative function of PCNA for therapeutic gains
has high potential to be effective in cancer treatment. We recently
reported that phosphorylation of PCNA at Y211 is a promising
treatment target in prostate cancer [23]. Our current results
suggest that targeting phospho-Y211 PCNA could be an effective
strategy in breast cancer treatment as well.
Materials and Methods
Cell culture, peptides, and antibodies
The breast cancer cell lines MDA-MB-231 and BT474 were
purchased from American Type Culture Collection (ATCC) and
grown in DMEM/F12 (1:1) with 10% fetal bovine serum. The
Figure 4. Targeting breast cancer cell line MDA-MB-231 with the Y211F peptide resulted in growth inhibition. A. Cells mock-treated
with vehicle alone or treated with the scramble or Y211F peptide (15 mM) were subjected to flow cytometry analysis. The percentages of cells in the
G1, S, and G2/M phases were plotted. B. DNA synthesis activity in the treated cells was determined by a colorimetric BrdU-incorporation analysis. For
each data point, the amount of incorporated BrdU was normalized to the percentage of viable cells, as determined by a side-by-side MTT assay.
doi:10.1371/journal.pone.0029416.g004
Figure 3. Y211 phosphorylation is an important growth signal downstream of c-Abl. The breast cancer cell lines MDA-MB-231 (A) and
BT474 (B) were treated with the Y211F peptide or the control scramble peptide at the indicated doses for 48 hours. Surviving cells were then
quantified by MTT assay and the results were plotted.
doi:10.1371/journal.pone.0029416.g003
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Facility of Yale University: TAT-conjugated peptides including the
wild-type Y211 non-phosphorylated peptide (WT; Figure 2E) (Ac-
CGRKKRRQRRRGTFALRYLNFFTK-CONH2), the wild-type
Y211-phosphorylated peptide (Y211-P; Figure 2E) (Ac-CGRKK-
RRQRRRGTFALRYpLNFFTK-CONH2), the Y211F peptide
(Ac-CGRKKRRQRRRGTFALRFLNFFTK-CONH2), the scram-
bled control peptide (Ac-CGRKKRRQRRRGFLFTNKLFRTAF-
CONH2), the purified N-terminally FAM-conjugated TAT-Y211F
peptide (FAM-TAT-Y211F; Figure 2B), and the Y211F peptide
without TAT sequence (FAM-Y211F; Figure 2B) were. The follow-
ing antibodies used in this study were purchased from a variety of
manufacturers: a-tubulin (Sigma; St. Louis, MO); c-Abl (BD
Pharmingen; San Jose, CA), Histone H3, PCNA (Santa Cruz; Santa
Cruz, CA), phospho-Y211 PCNA (Bethyl; Montgomery, TX).
Proliferation analysis
Cell proliferation was assessed by using a colorimetric BrdU
proliferation kit according to the manufacturer’s instructions
(Roche, Indianapolis, IN; Cat. No. 11647229001). Briefly, 1000 to
3000 cells per well were plated in 96-well plates in triplicate. The
experiments were repeated at least three times. Cells treated with
the peptides were labeled with BrdU for 3 to 4 h. The genomic
DNA was fixed and denatured, and then incubated with
peroxidase-conjugated anti-BrdU antibody for 90 min. A substrate
for the conjugated peroxidase was then added and the reaction
product was quantified by measuring the absorbance. The results
were then normalized by the number of total viable cells, which
was determined by a side-by-side cell-viability assay, as described
above.
Cell-cycle analyses by flow cytometry
Cells were harvested by trypsin, washed with PBS, and then
fixed in 70% ethanol. The fixed cells were stained with 25 mg/ml
propidium iodide (Sigma; St. Louis, MO) in the presence of 1 mg/
ml RNase (Sigma; St. Louis, MO). For fluorescence-activated cell
sorting (FACS) analysis, data were collected using a FACSCalibur
flow cytometer and analyzed using the software ModFit (Verity;
Topsham, ME). The cell-cycle distribution was evaluated by
counting .10,000 cells per sample.
Immunoprecipitation and western blotting analysis
Cells were lysed by incubation with NETN buffer (150 mM
NaCl, 1 mM EDTA pH 8.0, 20 mM Tris pH 8.0, 0.5% NP-40,
Figure 5. Growth inhibition of BT474 cells by targeting Y211 phosphorylation of PCNA. A. Cells mock-treated with vehicle alone or
treated with the scramble or Y211F peptides (15 mM) were subjected to flow cytometry analysis. The percentages of cells in the G1, S, and G2/M
phases were plotted. B. DNA synthesis activity in the treated cells was determined by a colorimetric BrdU-incorporation analysis. For each data point,
the amount of incorporated BrdU was normalized to the percentage of viable cells, as determined by a side-by-side MTT assay. C. Depletion of c-Abl
decreases sensitivity to Y211F peptide-mediated growth inhibition. A derivative of BT474 cells harboring an shRNA against c-Abl (BT474/shAbl ) or
luciferase (BT474/shLuc) were treated with 10 mM Y211F peptide or the scramble peptide for 48 h. Surviving cells were then assessed by MTT assay
and the results were plotted. *, P,0.05.
doi:10.1371/journal.pone.0029416.g005
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PMSF). For western analysis, the lysates were separated in
acrylamide gels, transferred to a PVDF membrane (Bio-Rad;
Hercules, CA), and probed with the indicated antibodies. Bands
were visualized by a chemiluminescence-based detection method
(Fisher/Pierce; Rockford, IL) that used horseradish peroxidase-
conjugated secondary antibodies. For immunoprecipitation, 1 to
2 mg of protein was used for each reaction. Proteins were
incubated with the antibody at 4uC overnight. Protein G agarose
was then added to precipitate the antibody-protein complex. The
Figure 6. IR induced Y211 phosphorylation of PCNA and its interaction with c-Abl. A. BT474 and MAD-MB-231 cells were irradiated
(10 Gy), and then incubated for 2 h. Cell lysates were immunoprecipitated by using the anti-phospho-Y211 antibody and then probed by western
blotting with an anti-PCNA antibody. The input amount of PCNA in the lysates was also assessed (lower panel). B. IR induced the interaction between
PCNA and c-Abl in breast cancer cells. Cells were treated as described in A, and then lysed. Endogenous c-Abl was immunoprecipitated by using an
anti–c-Abl antibody, and the co-precipitated PCNA and c-Abl were detected by western analysis. C. BT474 cells were treated with the Y211F peptide
or the scramble peptide (10 mM) for 12 h, then irradiated (10 Gy), followed by incubation for 36 h. Surviving cells were then assessed by MTT assay.
Relative cell viability (y axis) denotes reduced cell survival compared with the scramble control, which is defined as 100%.
doi:10.1371/journal.pone.0029416.g006
Figure 7. c-Abl enhances chromatin association and PCNA foci formation in response to DNA damage. A. MDA-MB-231/shAbl and
MDA-MB-231/shCtrl cells were exposed to 10 Gy of IR. Following one hour of incubation, the cells were extracted with 0.5% of Triton X-100. Levels of
PCNA in the soluble and insoluble fractions were examined by western analysis. Expression of a-tubulin and histone H3 was assessed as markers of
the soluble and insoluble fractions, respectively. B. c-Abl is important in the formation of PCNA nuclear foci. MDA-MB-231/shAbl and MDA-MB-231/
shCtrl cells were mock-treated or irradiated with 10 Gy of IR followed by incubation for one hour. Cells were then fixed with methanol and stained
with an anti-PCNA antibody. C. To evaluate the number of foci-positive cells, five independent fields representing each treatment were counted. The
experiment was repeated two times, and the results of the two trials were consistent.
doi:10.1371/journal.pone.0029416.g007
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immunocomplexes were then released by boiling in 26 loading
buffer followed by western blotting analysis, as described.
Immunofluorescence confocal microscopy
Cells were fixed and then permeabilized by methanol and 0.5%
Triton X-100 for 10 minutes at room temperature. After four
washes with PBS, the cells were blocked with 10% normal goat
serum for 1 hour at room temperature, and then immunostained
with primary antibody against PCNA (1:200 dilution in PBS with
0.2% BSA) overnight at 4uC. After three washes with PBS, the
FITC-conjugated secondary antibody was applied for 45 minutes
at room temperature. Images were captured with a Zeiss laser
scanning confocal microscope (LSM510). For localization analysis
of the FAM-labeled peptides, cells were treated with the peptide at
7.5 mM for 30 min. Treated cells were then washed twice with
PBS, and fixed with 4% paraformaldehyde. Peptide localization
was visualized by fluorescence confocal microscopy as described
above.
Statistical analysis
Data from each assay were expressed as means 6 SD (n=3).
Statistical differences between two groups were determined by the
Student’s t-test. P,0.05 was considered significantly different.
Supporting Information
Figure S1 Expression of FLAG-PCNA in HEK293T cells.
Cells were transfected with FLAG-PCNA (wild-type, Y211F) or
the empty vector (pcDNA3). The lysates of the transfected cells
were analyzed by western blotting using an anti-PCNA antibody
(Santa Cruz; Santa Cruz, CA). Both the endogenous (endo PCNA)
and the FLAG-tagged ectopic PCNA (Flag-PCNA) were shown as
indicated by the arrows.
(TIF)
Figure S2 Assess the putative PCNA-binding motif of c-
Abl. The c-Abl mutant c-Abl/QI-AA had no effect on the
interaction between PCNA and c-Abl. HEK293T cells were
transfected with the cDNA of the Myc-tagged wild-type or QI-AA
mutant of c-Abl or the control vector. Cell lysates were then
immunoprecipitated with an anti-Myc antibody. The levels of co-
precipitated endogenous PCNA were determined by western
analysis using an anti-PCNA antibody.
(TIF)
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